{"product_id":"new-product-637286","title":"CLIA Kit for Phospholipase A2 Group VII (LpPLA2)","description":"\u003cp\u003eChemiluminescent immunoassay for Antigen Detection.\u003c\/p\u003e\n\u003cp\u003eProduct No.\u003c\/p\u003e\n\u003cp\u003eSCA867Hu\u003c\/p\u003e\n\u003cp\u003eOrganism Species\u003c\/p\u003e\n\u003cp\u003eHomo sapiens (Human).\u003c\/p\u003e\n\u003cp\u003eSample Type\u003c\/p\u003e\n\u003cp\u003eSerum, plasma and other biological fluids\u003c\/p\u003e\n\u003cp\u003eTest Method\u003c\/p\u003e\n\u003cp\u003eDouble-antibody Sandwich\u003c\/p\u003e\n\u003cp\u003eAssay Length\u003c\/p\u003e\n\u003cp\u003e2h, 40min\u003c\/p\u003e\n\u003cp\u003eDetection Range\u003c\/p\u003e\n\u003cp\u003e13.7-10,000pg\/mL\u003c\/p\u003e\n\u003cp\u003eSensitivity\u003c\/p\u003e\n\u003cp\u003eThe minimum detectable dose of this kit is typically less than 4.8pg\/mL.\u003c\/p\u003e\n\u003cp\u003eUOM\u003c\/p\u003e\n\u003cp\u003e48T 96T 96T*5 96T*10 96T*100\u003c\/p\u003e\n\u003ch3\u003eSpecificity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThis assay has high sensitivity and excellent specificity for detection of Phospholipase A2 Group VII (LpPLA2).\u003cbr\u003eNo significant cross-reactivity or interference between Phospholipase A2 Group VII (LpPLA2) and analogues was observed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eRecovery\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eMatrices listed below were spiked with certain level of recombinant Phospholipase A2 Group VII (LpPLA2) and the recovery rates were calculated by comparing the measured value to the expected amount of Phospholipase A2 Group VII (LpPLA2) in samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eRecovery range (%)\u003c\/td\u003e\n\u003ctd\u003eAverage(%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e79-104\u003c\/td\u003e\n\u003ctd\u003e91\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e95-102\u003c\/td\u003e\n\u003ctd\u003e99\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e85-105\u003c\/td\u003e\n\u003ctd\u003e94\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003ePrecision\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) were tested 20 times on one plate, respectively.\u003cbr\u003eInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) were tested on 3 different plates, 8 replicates in each plate.\u003cbr\u003eCV(%) = SD\/meanX100\u003cbr\u003eIntra-Assay: CV\u0026lt;10%\u003cbr\u003eInter-Assay: CV\u0026lt;12%\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eLinearity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Phospholipase A2 Group VII (LpPLA2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample\u003c\/td\u003e\n\u003ctd\u003e1:2\u003c\/td\u003e\n\u003ctd\u003e1:4\u003c\/td\u003e\n\u003ctd\u003e1:8\u003c\/td\u003e\n\u003ctd\u003e1:16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e86-94%\u003c\/td\u003e\n\u003ctd\u003e78-95%\u003c\/td\u003e\n\u003ctd\u003e91-105%\u003c\/td\u003e\n\u003ctd\u003e81-92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e78-92%\u003c\/td\u003e\n\u003ctd\u003e80-95%\u003c\/td\u003e\n\u003ctd\u003e98-105%\u003c\/td\u003e\n\u003ctd\u003e90-104%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e87-94%\u003c\/td\u003e\n\u003ctd\u003e90-104%\u003c\/td\u003e\n\u003ctd\u003e92-101%\u003c\/td\u003e\n\u003ctd\u003e79-90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003eStability\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\u003cbr\u003eTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eReagents and materials provided\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"reagent_div\"\u003e\n\u003ctable class=\"reagent_table\"\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-coated, ready to use 96-well strip plate\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePlate sealer for 96 wells\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandard\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eStandard Diluent\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent A\u003c\/td\u003e\n\u003ctd\u003e1×120µL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent A\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent B\u003c\/td\u003e\n\u003ctd\u003e1×120µL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent B\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubstrate A\u003c\/td\u003e\n\u003ctd\u003e1×10mL\u003c\/td\u003e\n\u003ctd\u003eSubstrate B\u003c\/td\u003e\n\u003ctd\u003e1×2mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWash Buffer (30 × concentrate)\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003ctd\u003eInstruction manual\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eAssay procedure summary\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003e1. Prepare all reagents, samples and standards;\u003cbr\u003e2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;\u003cbr\u003e3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;\u003cbr\u003e4. Aspirate and wash 3 times;\u003cbr\u003e5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;\u003cbr\u003e6. Aspirate and wash 5 times;\u003cbr\u003e7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;\u003cbr\u003e8. Read RLU value immediately.\u003cbr\u003e\u003c\/p\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScience \u0026amp; Sports\u003c\/td\u003e\n\u003ctd\u003eThe effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0765159710000262\" target=\"_blank\"\u003eScienceDirect: S0765159710000262\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolic Syndrome and Related Disorders\u003c\/td\u003e\n\u003ctd\u003eAssociation of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/online.liebertpub.com\/doi\/abs\/10.1089\/met.2011.0111\" target=\"_blank\"\u003eWiley: source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e34\u003c\/td\u003e\n\u003ctd\u003eEffects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22240497\" target=\"_blank\"\u003ePubMed: 22240497\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLoS ONE\u003c\/td\u003e\n\u003ctd\u003eEffects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3759413\/\" target=\"_blank\"\u003ePubMed: PMC3759413\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina Pharmacy\u003c\/td\u003e\n\u003ctd\u003eInfluence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/115.28.47.44:8080\/UploadFiles\/zzlw\/2013\/7\/201307020918353864.pdf\" target=\"_blank\"\u003eSource\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtherosclerosis\u003c\/td\u003e\n\u003ctd\u003eEverolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23958269\" target=\"_blank\"\u003ePubmed: 23958269\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Diabetes Research\u003c\/td\u003e\n\u003ctd\u003eLipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.hindawi.com\/journals\/jdr\/2014\/278063\/abs\/\" target=\"_blank\"\u003eHindawi: 278063\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth\u003c\/td\u003e\n\u003ctd\u003eThe Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/file.scirp.org\/Html\/15-8202855_47116.htm\" target=\"_blank\"\u003eScirp:Source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiology Bulletin\u003c\/td\u003e\n\u003ctd\u003eIn vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/link.springer.com\/article\/10.1134\/S1062359015010112\" target=\"_blank\"\u003eSpringer:Source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGynecol Endocrinol.\u003c\/td\u003e\n\u003ctd\u003eLipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24397392\" target=\"_blank\"\u003ePubmed:24397392\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Diabetes Research\u003c\/td\u003e\n\u003ctd\u003eLipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24818163\" target=\"_blank\"\u003ePubmed:24818163\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolism.\u003c\/td\u003e\n\u003ctd\u003eEffects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25034387\" target=\"_blank\"\u003ePubmed:25034387\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ Am Heart Assoc\u003c\/td\u003e\n\u003ctd\u003eEffect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26374297\" target=\"_blank\"\u003ePubMed: 26374297\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCzecho-Slovak Dermatology \/ Cesko-Slovenska Dermatologie\u003c\/td\u003e\n\u003ctd\u003eV\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/search.ebscohost.com\/login.aspx?direct=true\u0026amp;profile=ehost\u0026amp;scope=site\u0026amp;authtype=crawler\u0026amp;jrnl=00090514\u0026amp;AN=110723148\u0026amp;h=m0xSKuLLzFAHpP68AaY9CkcNZYGUG13sfJiiMF7zxsutbZsQiIItSLucGfiuXaRkppeeycbc%2F38jRj%2F2Rq32pQ%3D%3D\u0026amp;crl=c\" target=\"_blank\"\u003eEbscohost\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndocrinol Metab (Seoul).\u003c\/td\u003e\n\u003ctd\u003eEffect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4803547\/\" target=\"_blank\"\u003epmc:PMC4803547\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClin Pharmacol Ther. \u003c\/td\u003e\n\u003ctd\u003eEffect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25773594\" target=\"_blank\"\u003ePubmed:25773594\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLipids in Health and Disease\u003c\/td\u003e\n\u003ctd\u003eEffect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-016-0368-3\" target=\"_blank\"\u003earticles:10.1186\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActa Endocrinologica\u003c\/td\u003e\n\u003ctd\u003eSERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/search.ebscohost.com\/login.aspx?direct=true\u0026amp;profile=ehost\u0026amp;scope=site\u0026amp;authtype=crawler\u0026amp;jrnl=18410987\u0026amp;AN=129359477\u0026amp;h=uZUGA2wl9xcqhmQWswepQQJouj8KXPxELZeK8Fb9ovM3TuJHuwVGHwWNGhl%2F4%2FzFKdGq9EO6KwYaY8Y7P4doMQ%3D%3D\u0026amp;crl=c\" target=\"_blank\"\u003ejrnl:1841098\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eBiomarker for diagnosis of moyamoya disease\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.cloud-clone.com\/products\/SCA867Hu.html\" target=\"_blank\"\u003e:\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION\u003c\/td\u003e\n\u003ctd\u003eCirculating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32859455\/\" target=\"_blank\"\u003ePubmed: 32859455\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003echinese neurosurgical journal\u003c\/td\u003e\n\u003ctd\u003eCan admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?\u003ca rel=\"nofollow\" href=\"https:\/\/cnjournal.biomedcentral.com\/articles\/10.1186\/s41016-020-00188-z\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Homo sapiens (Human) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA867Hu02\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA867Hu02.html\"\u003eRecombinant Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA867Hu03\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA867Hu03.html\"\u003eRecombinant Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA867Hu04\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA867Hu04.html\"\u003eRecombinant Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPA867Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/APA867Hu01.html\"\u003eActive Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eCell culture; Activity Assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA867Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA867Hu01.html\"\u003eRecombinant Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAA867Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/PAA867Hu01.html\"\u003ePolyclonal Antibody to Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAA867Hu81\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LAA867Hu81.html\"\u003eFITC-Linked Polyclonal Antibody to Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IF.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAA867Hu71\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LAA867Hu71.html\"\u003eBiotin-Linked Polyclonal Antibody to Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA867Hu21\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA867Hu21.html\"\u003eMonoclonal Antibody to Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA867Hu22\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA867Hu22.html\"\u003eMonoclonal Antibody to Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEA867Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEA867Hu.html\"\u003eELISA Kit for Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCA867Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SCA867Hu.html\"\u003eCLIA Kit for Phospholipase A2 Group VII (LpPLA2)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eChemiluminescent immunoassay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMA867Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LMA867Hu.html\"\u003eMagnetic Luminex Assay Kit for Phospholipase A2 Group VII (LpPLA2) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"96T \/ The minimum detectable dose of this kit is typically less than 4.8pg\/mL \/ 13.7-10,000pg\/mL","offer_id":47589914149144,"sku":"SCA867Hu","price":840.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/SE_BIG_ff356b60-b64f-40fd-b07d-7319c4f8688a.jpg?v=1706211123","url":"https:\/\/danabiosci.com\/products\/new-product-637286","provider":"Dana Bioscience","version":"1.0","type":"link"}